Population Pharmacokinetics of Tigecycline in Patients Treated With ECMO
试验速览
- 阶段
- 不适用
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Serum drug concentration of tigecycline
研究概览
简要总结
Tigecycline is a commonly used antibiotic in critically ill patients. The pharmacokinetics (PK) of tigecycline in intensive care unit (ICU) patients can be affected by severe pathophysiological changes so that standard dosing might not be adequate. At present, a number of studies have reported that ECMO will affect the PK of anti-infective drugs and lead to treatment failure. The purpose of this study was to describe the population PK of tigecycline in patients treated with ECMO and to evaluate the relationship between individual PK parameters and patient covariates.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •critically ill hospitalized males or nonpregnant females aged ≥18 years with severe infections which the treating clinician was treating with tigecycline.
排除标准
- •People who had taken tigecycline in the past week
- •People who were pregnant
- •People who had coagulation dysfunction
结局指标
主要结局
Serum drug concentration of tigecycline
时间窗: predose, 2 min, 5 min, 15 min, 30 min, 1 hour, 3 hours, 6 hours, 12 hours, and 24 hours post-dose
Serum drug concentration at different time points in each adult ICU patient treated with ECMO
次要结局
未报告次要终点
研究者
Zhenhua Zen
Associate Professor
Nanfang Hospital, Southern Medical University